Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gustavo Peralta-Sánchez"'
Autor:
Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, Araceli Tepale-Segura, Julián Gajón-Martínez, Tania Rivera-Hernández, Eduardo Antonio Ferat-Osorio, Arturo Cérbulo-Vázquez, Lourdes Andrea Arriaga-Pizano, Laura Bonifaz, Georgina Paz-De la Rosa, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, David Sarfati-Mizrahi, Weina Sun, Héctor Elías Chagoya-Cortés, Peter Palese, Florian Krammer, Adolfo García-Sastre, Bernardo Lozano-Dubernard, Constantino López-Macías
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSeveral effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, the current production capacity falls short of meeting global demand. Therefore, i
Externí odkaz:
https://doaj.org/article/f59adc9f44cc4bf6920104dbbb786afe
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Autor:
Samuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán-Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, Claudia Carranza, Esmeralda Juárez, Laura E. Carreto-Binaghi, Luis Ramírez-Martínez, Georgina Paz De la Rosa, Rosalía Vigueras-Moreno, Alejandro Ortiz-Stern, Yolanda López-Vidal, Alejandro E. Macías, Jesús Torres-Flores, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, Hisaaki Kawabata, Irene González-Domínguez, José Luis Martínez-Guevara, Weina Sun, David Sarfati-Mizrahi, Ernesto Soto-Priante, Héctor Elías Chagoya-Cortés, Constantino López-Macías, Felipa Castro-Peralta, Peter Palese, Adolfo García-Sastre, Florian Krammer, Bernardo Lozano-Dubernard
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-14 (2023)
Abstract There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a
Externí odkaz:
https://doaj.org/article/d2ac0c69327549fb9217708e2039498c
Autor:
Samuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán-Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, Claudia Carranza, Esmeralda Juárez, Laura E. Carreto-Binaghi, Luis Ramírez-Martínez, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Alejandro Ortiz-Stern, Yolanda López-Vidal, Alejandro E. Macías, Jesús Torres-Flores, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, Hisaaki Kawabata, Irene González-Domínguez, José Luis Martínez-Guevara, Weina Sun, David Sarfati-Mizrahi, Ernesto Soto-Priante, Héctor Elías Chagoya-Cortés, Constantino López-Macías, Felipa Castro-Peralta, Peter Palese, Adolfo García-Sastre, Florian Krammer, Bernardo Lozano-Dubernard
Publikováno v:
medRxiv
There is still a need for safe, efficient and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bde479e654e6ef0648aed025d62266a
https://pubmed.ncbi.nlm.nih.gov/35169806
https://pubmed.ncbi.nlm.nih.gov/35169806